Strategic Shifts: New Research Defines Best Ways to Switch Osteoporosis Meds

Effective long-term management of osteoporosis requires a carefully choreographed sequence of medications, as certain drug transitions can significantly enhance or inadvertently undermine bone density, according to a clinical review published by researchers at Aarhus University. The article, “ Approach to the Patient—Transitions in Osteoporosis Therapy ,” appearing in The Journal of Clinical Endocrinology & Metabolism , emphasizes that a “goal-directed” treatment strategy is essential for preventing fractures.

While most transitions between bone-building (anabolic) and bone-preserving (antiresorptive) drugs are beneficial, the research team identified specific “danger zones” — particularly involving the drug denosumab — where incorrect timing or discontinuation can lead to rapid bone loss and increased fracture risk. For many patients, a single medication is not enough to maintain healthy bone mineral density (BMD) over a lifetime.

The article found that the most effective sequence involves starting with an anabolic agent — a drug, such as teriparatide, abaloparatide, and romosozumumab that actively builds new bone — followed by an antiresorptive agent, such as bisphosphonates or denosumab, to “lock in” and further improve those gains.